BMJ Retracts PREVENT-TAHA8 Stem Cell Heart Failure Trial
The BMJ has retracted the PREVENT-TAHA8 phase 3 trial on mesenchymal stem cells for heart failure due to data integrity and enrollment concerns.
By James Liu
2 articles tagged "heart failure"
The BMJ has retracted the PREVENT-TAHA8 phase 3 trial on mesenchymal stem cells for heart failure due to data integrity and enrollment concerns.
NICE updates chronic heart failure guidance, covering pharmacological optimisation across ejection fraction subtypes and IV iron supplementation recommendations.